IMCOR PHARMACEUTICAL CO Form SC 13G November 08, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.____) * IMCOR PHARMACEUTICAL CO. (Name of Issuer) Series "A" Convertible Preferred Stock, \$0.01 par value (Title of Class of Securities) Not applicable. (CUSIP Number) October 29, 2004 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [] Rule 13d-1(b) [X] Rule 13d-1(c) [] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange

Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see

CUSIP NO. -- Not applicable

the Notes).

1. NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Bristol-Myers Squibb Company 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [] (b) [X] ______ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5. SOLE VOTING POWER NUMBER OF SHARES 6. SHARED VOTING POWER BENEFICIALLY 16,666,667 OWNED BY ______ 7. SOLE DISPOSITIVE POWER REPORTING _____ PERSON 8. SHARED DISPOSITIVE POWER WITH 16,666,667 ______ 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 16,666,667 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 17.2% 12. TYPE OF REPORTING PERSON ______ Item 1(a). Name of Issuer: Imcor Pharmaceutical Co.

Address of Issuer's Principal Executive Offices:

Item 1(b).

6175 Lusk Boulevard San Diego, CA 92121

Item 2(a). Name of Persons Filing:
Bristol-Myers Squibb Company

> Bristol-Myers Squibb Company 345 Park Avenue New York, NY 10154

Item 2(e).

CUSIP Number:
Not applicable.

Item 3. Not applicable. This Statement on Schedule 13G was filed pursuant to Rule 13d-1(c).

Item 4. Ownership.

- (a). Amount beneficially owned: See the response to Item 9 on the attached cover page. Bristol-Myers Squibb Company (BMS) directly owns 4,500 shares of the Series "A" Convertible Preferred Stock ("Preferred Stock"). Each share of Preferred Stock is convertible into approximately 3,703.8 shares of the Issuer's common stock. The 4,500 shares of Preferred Stock directly owned by BMS is currently convertible into approximately 16,666,667 shares and represents beneficial ownership of approximately 17.2% of the Issuer's common stock.
- (b). Percent of Class: See the response to Item 11 on the attached cover page. BMS beneficially owns approximately 16,666,667 shares of common stock, representing beneficial ownership of approximately 17.2% of the shares of common stock outstanding.
- (c). Number of shares as to which such person has:
 - (i). Sole power to vote or to direct the vote: See the response to Item 5 on the attached cover page.
 - (ii). Shared power to vote or to direct the vote: See the response to Item 6 on the attached cover page.
 - (iii). Sole power to dispose or to direct the disposition of: See the response to Item 7

on the attached cover page.

(iv). Shared power to dispose or to direct the disposition of: See the response to Item 8 on the attached cover page.

Item 5. Ownership of Five Percent or Less of a Class. Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not Applicable.

Item 8. Identification and Classification of Members of the Group. Not Applicable.

Item 9. Notice of Dissolution of Group. Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 8, 2004

BRISTOL-MYERS SQUIBB COMPANY

/s/ Sandra Leung

Name: Sandra Leung

Title: Vice President and Corporate Secretary